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Summary Oestrone sulphatase may be an important means of production of intra-tumoural oestrogens in
breast cancer cells. The N-nitrosomethylurea induced rat mammary tumours, which is a good model ofhuman
breast carcinoma, was utilised to examine the significance of intra-tumoural oestrone sulphatase levels. The
particular fraction (100,000 g pellet) was prepared from both the liver and the tumour of NMU treated rats
and assayed for sulphatase activity. The tumour enzyme had an optimum pH of 7.2, Km value of 14.8 ytM and
Vmax of 0.90 nmoles min-' mg-', while the hepatic enzyme was optimal at pH 7.4, Km of 10.8 fM and Vmax
of 3.71 nmoles min' mg '. The relationship of intra-tumoural sulphatase levels with tumour regression and
progression in endocrine responsive tumours was investigated. Tumour regression as a result of oophorectomy
was associated with a significantly decreased intra-tumoural sulphatase level (mean level = 0.165 nmoles
min-' mg ') in comparison to a control group (mean level = 0.319 nmoles min-' mg-', P<0.05) in which the
tumours remained stable. This significant difference was not observed in the corresponding hepatic samples
suggesting that it is the intra-tumoural rather than the peripheral production of oestrogens by oestrone
sulphatase that is important in supporting growth of endocrine responsive tumours.
Approximately one third of human breast carcinomas are
hormone-dependent (Henderson & Canellos, 1980), oestro-
gens being the most important hormones involved in
supporting growth of hormone-dependent breast tumours
(Segaloff, 1978; Kirschner, 1979). Plasma levels of oestrone
and oestradiol in postmenopausal women are very low, how-
ever the oestrogen concentration in breast tumour tissues is
an order ofmagnitude higher than in the plasma (Millington,
1975; Edery et al., 1981; Fishman et al., 1977; Thorsen et al.,
1982; van Landeghem et al., 1985; Thijssen & Blankenstein,
1989), suggesting local intra-tumoural production of oestro-
gens in breast tumour cells from precursor substrates. A
comparative study of intra-tumoural aromastase and oest-
rone sulphatase activities has demonstrated that the sulpha-
tase appears to be at least ten times more active than the
aromatase enzyme in the production of intra-tumoural oest-
rogens from their respective precursor substrates (Santner et
al., 1984). Therefore the sulphatase pathway is likely to be an
important means of local production of biologically active
oestrogens in human breast carcinoma tissue.
The N-nitrosomethylurea-induced mammary gland carcin-
oma in rat is a good model of human breast carcinoma
(Gullino et al., 1975). It is a hormone dependent model that
regresses on oophorectomy and responds to anti-endocrine
agents (Williams et al., 1981; Wilkinson et al., 1986). When
these mammary tumours are grown in soft agar, colony
formation is stimulated by oestrone sulphate. This is accom-
panied by the conversion of oestrone sulphate to oestradiol
(Santner et al., 1986). An in vivo study demonstrated that
oestrone sulphate can stimulate the growth of NMU-induced
mammary tumour in castrate animals (Santner et al., 1990).
This tumour contains levels of oestrone sulphatase activity
similar to human tumours (Santner et al., 1984). The aim of
this study was to determine intra-tumoural oestrone sulpha-
tase activity in NMU-induced mammary tumours that re-
gress with endocrine manipulation and in tumours which
progress under oestrogenic stimulation. Previously, the rat
and human oestrone sulphatase have been shown to be
membrane-bound (Kawano et al., 1989; MacIndoe et al.,
1988; Dolly et al., 1972) therefore we have prepared the
particulate fraction (100,000 g pellet) as a source of the
enzyme.
Materials and methods
Reagents
[6,7-3H] Oestrone sulphate (specific activity 47.7Cimmol-1)
was purchased from New England Nuclear Division (Du
Pont, UK, Ltd). Purity was checked by thin layer chromato-
graphy on silica gel (Merck 5415 Kieselgel F 254) using the
following solvent system: ethyl actate, methanol, ammonium
hydroxide 75:25:2 (vol/vol/vol). [4-'4C] oestrone (specific
activity 60 Ci mmol ') was purchased from Amersham Inter-
national (Amersham, UK).
Animals
Inbred virgin female (Ludwig/Wistar/Olac) rats induced with
NMU were supplied by Olac, Oxon, England. In all studies,
adult rats between 2 and 3 months old and weighing
200-250 grams were used. Rats bearing mammary tumours
between 10-20 mm in diameter were randomised into appro-
priate groups. Tumour measurements were performed at the
beginning of each experiment and at weekly intervals subse-
quently by measurement of two diameters at 90° using ver-
nier callipers.
For the hormone-dependent tumour regression study, 24
animals bearing mammary tumours were randomised into
two groups of 12 animals. In one group, each of the 12
animals was subjected to oophorectomy, in the other group a
'sham' laparotomy was performed on each of the 12 animals.
Animals were sacrificed when their tumours had regressed by
at least 50%, and an animal from the control group was
sacrificed concurrently. For the hormone-dependent tumour
progression study, 24 animals bearing mammary tumours
were randomised into two further groups of 12 animals each.
The animals in the oestrogen-treated group were injected
with oestradiol at a dose of 0.Ijg kg-' in 0.2 ml of 0.9%
NaCl subcutaneously daily for 5 days every week of the
experiment. The rats in the control groups were similarly
injected with 0.2 ml of 0.9% NaCl on the same days. The
experiment was terminated by sacrificing all animals after 4
weeks.
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In both experiments the tumours and liver were harvested
from all rats, immediately frozen in liquid nitrogen and
stored at -70C. Tumour volumes were calculated using the
formula in (d, x d2) i
Tissue preparation
All procedures were carried out at 0-4°C. The tumour was
chopped with scissors and homogenised in 0.25 M sucrose in
50 mM Tris/HCl buffer pH 7.4 (1 g tissue to 6 ml buffer)
using a Polytron homogeniser at setting no. 5 for 15 s. The
homogenate was subjected to subcellular fractionation. The
nuclear pellet was obtained by centrifugation at 1,500g for
15 min, followed by centrifugation at 100,000g for 70 min to
separate the particular fraction from the cytosol. All pellets
were resuspended in 50 mM Tris/HCl buffer pH 7.4, snap
frozen at - 80C and stored at -20°C. The particulate frac-
tion of all tumour samples were assayed for oestrone sulpha-
tase activity and the protein content determined by the
method of Hartree (Hartree, 1972). The rat hepatic subcellu-
lar fractions were similarly prepared, except that 1 g of tissue
was dissolved in 10 ml of 0.25 M sucrose in 50 mM Tris/HCI
buffer, pH 7.4.
Oestrone sulphatase assay
The enzyme was assayed by measuring the total 3H-labelled
non-polar metabolites formed from 3H oestrone sulphate by
ether solvent partition (MacIndoe et al., 1988; Naitoh et al.,
1989). Before use in the assay, oestrone sulphate was purified
by solvent partition with diethyl ether (5:1 vol/vol) in order
to remove any unconjugated steroids. Radiolabelled oestrone
sulphate was added to the unlabelled compound to achieve
the required concentration. All assays were carried out in
duplicate at 37°C in a shaking waterbath. Tubes were prein-
cubated for 1 min before initiating the reaction by addition
of the tissue samples. The assay tubes (volume 0.3 ml) con-
taining 10 mM DTT (dithiothreitol), 1 mM EDTA, 20 tLM 3H
oestrone sulphate (approximately 4 x 105 c.p.m.), tissue sam-
ple and 50 mM Tris/HCI buffer at the relevant pH.
Aliquots (0.1 ml) were removed from each assay tube after
10 min and 20 min of incubation to ensure linearity of pro-
duct formation. The reaction was terminated by addition of
each aliquot to a chilled tube containing 0.1 ml of 0.1 M
sodium carbonate and [4-'4C]oestrone (approximately 5,000
c.p.m.) as internal standard. The unconjugated product was
separated from the substrate by adding 3 ml of ether and left
to stand at room temperature. After drying with anhydrous
sodium sulphate, the ether layer was separated by centrifuga-
tion and added to a scintillation vial. The same was evapor-
ated to dryness under nitrogen and reconstituted with 1Oml
scintillation fluid and radioactivity determined by liquid scin-
tillation counting. The recovery of the internal standard was
used to correct the amount of tritiated product formed.
The method was modified in order to identify the products
of the oestrone sulphatase enzyme reaction. The extracted
ether phase was dried, centrifuged, and taken to dryness as
before, then reconstituted with a small volume (251Al) of
ethyl acetate. A 200jsl aliquot of the ether layer had been
taken for counting before the remainder was taken to dry-
ness. The reconstituted sample was run on a TLC plate,
using the solvent system dichloromethane:ether (9:1 vol/vol).
The silica corresponding to the radioactive peak was scraped
off the TLC plate, dissolved in methanol, an aliquot retained
for counting and the remainder was taken to dryness, recon-
stituted in 25jil ethyl acetate and run on a second TLC plate,
using the solvent system ethyl acetate: benzene (1:1 vol/vol).
Again the silica peaks were scraped off and an aliquot taken
for counting. The plates were scanned using a Berthold LB
283 linear analyser and the radioactive peaks compared with
authenthic steroids.
Results
Evaluation ofoptimal assay conditions
In both tumour and hepatic particular fractions, there was a
linear relationship of increasing enzyme activity with increas-
ing protein concentration (up to 0.2;Lgml-'), and in addition
all assays displayed linear product formation up to 20min,
demonstrating that the enzyme was assayed under saturating
conditions.
The Km and Vmax were calculated by the Eadie-Hofstee
method. In the rat tumour particulate fraction the Km was
14.8I1M, and the Vmax was 0.90 nmolesmin-'mg-' and in
the rat hepatic particulate fraction the Km was 10.8jAM, and
the Vmax was 3.71 nmolesmin-I mg- (Figure 1). The recip-
rocal plots for both tissue enzymes were linear in nature with
no evidence of substrate activation or product inhibition. The
optimum pH for the rat tumour particulate fraction is Tris/
HCI pH 7.2 (Figure 2), for rat hepatic particulate fraction,
7.4.
With both solvent samples only one peak was seen for
both the tumour enzyme product and the hepatic enzyme
product, in each case corresponding to the Rf value of cold
oestrone as visualised by UV light. With the dichlorometh-
ane:ether (9:1 vol/vol) system, the Rf value was 0.39. With
the ethyl actate:benzene (1:1 vol/vol) system the Rf value was
0.47. The 3H:14C ratio of the products remained constant
after the ether extraction and after the sequential TLC
analysis (Table I). This demonstrates that the only 3H-
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Figure 1 Eadie - Hofstee plot for the rat hepatic particulate
fraction. Km = 10.8 jAM. Vmax = 3.71 nmoles min-' mg-'.
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Figure 2 Optimum pH curve for the rat tumour particulate
fraction. Mes/HCl: *-*; Tris/HCI: 0-0; Glycine/NaOH:
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Table I Purity of 3H oestrone. 3H:14C-ratio
Ether Dichloromethane:ether Benzene:Ethyl acetate
Sample extraction [9:1] [1:1]
Rat tumour 5.15:1 4.97:1 4.99:1
Rat liver 6.45:1 6.46:1 6.40:1
labelled metabolite formed is oestrone and this is essentially
pure at the ether extraction phase.
To determine the variation in enzyme activity across a
single tumour, particulate fraction were assayed from two
different samples from the same tumour for each of three
tumours. These tumours were from three separate animals
selected at random, but not included in the above experi-
ment. The specific activity of oestrone sulphatase enzyme in
these pairs of samples from the three tumours were: 0.42,
0.37; 0.18,0.16; 0.21,0.19; (all values nmoles min' mg').
Tumour measurements: oestradiol treated and control group
One rat which had been treated with oestradiol died at the
beginning of week 3 due to an ulcerating progressive tumour
which was not harvested. A further rat from the same group
was sacrificed electively also at week 3 and its tumour and
liver harvested in the usual way. All other animals were
sacrificed after 4 weeks.
Tumour volumes of the control and oestradiol-treated
groups were comparable on day 0 (P = 0.80, Mann Whitney
test). Comparison of the % change in tumour volume
between day 0 and day 28 demonstrated that tumour pro-
gression was significantly increased by the administration of
oestradiol (P = 0.03, Mann Whitney test), (Table II, Figure
3). There were four new tumours in the oestradiol group, and
two new tumours in the control group.
Tumour measurements: oopherectomy and laparotomy groups
The initial tumour volume were comparable in the two
groups. One new tumour appeared in the oophorectomy
Table II Rat tumours
Oestradiol treated Control NaCl
No. of rats 12 12
No. of initial tumours 18 15
No. new tumours 4 2
Regression >50% 0 1
Regression <50% 1 2
Progression 11 9
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group, no new tumours in the control laparotomy group. In
all but one of the oophorectomised animals, the tumour
volume had regressed by greater than 50% by the second
week and were sacrificed at that time and a control animal
also at the same time. The other oophorectomised animal's
tumour had likewise regressed by more than 50% by the
third week, and was sacrificed at that time alone with the
remaining control animal. Whereas the tumours in all 12
oophorectomised animals regressed by greater than 50% of
their initial volume, none of the tumours in the control
'sham' laparotomy animals regressed; in fact tumour volume
progressed by more than 50% in five of these animals and
remained stable in the other seven animals (Table III, Figure
4).
Intra-tumoural sulphatase level
All tumours had sulphatase activity. In the oophorectomy
group, the mean activity was 0.165 nmoles min-' mg-' (n =
12, range 0.071 to 0.335 nmoles min' mg') while in the
control 'sham' laparatomy group the mean activity was 0.319
nmoles min' mg'1 (n = 12, range 0.149 to 0.887 nmoles
min-'1 ml). The intra-tumoural sulphatase levels were signi-
ficantly reduced in those tumours that had regressed follow-
ing endocrine treatment (oophorectomy) in comparison with
the intra-tumoural sulphatase levels found in the correspond-
ing control ('sham' laparotomy) group which had remained
stable (P<0.05, Mann-Whitney test), (Figure Sb). In the
tumour progression experiment, again all tumours displayed
sulphatase activity. In the oestradiol treated group, mean
sulphatase specific activity was 0.175nmolesmin lmg'1
(n = 11, range 0.055 to 0.477 nmoles min- ng-) and in the
control (NaCl treated) group mean specific activity was 0.187
nmoles min' mg-' (n = 12, range 0.075 to 0.307 nmoles
min- mg-'). This was not significantly different (Figure 5a).
Hepatic sulphatase levels
All samples had sulphatase activity, and of an order of
magnitude higher than in the tumour samples. In the
tumours that regressed, there was no significant difference
Table III Rat tumours
Oophorectomy Control laparotomy
No. of rats 12 12
No. of initial tumours 16 16
No. new tumour 0 1
Regression >50% 12 0
Regression <50% 0 0
Progression 0 5
Weeks Weeks
Figure 3 Growth curve of oestradiol and NaCI control treated
rats, expressed as % of original tumour volumes. Oestradiol
treated: *; Control NaCl treated: 0-0.
Figure 4 Growth curve of rats treated by oophorectomy and
'sham' laporotomy (control), expressed as % of original tumour
volumes. Oophorectomy: 0 0; Laparotomy: * *.OESTRONE SULPHATASE IN RAT MAMMARY TUMOUR MODEL 75
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Figure 5 Scatter diagram of intra-tumoural oestrone sulphatase
activity in experimental animals groups. a, Control and oestradiol
treated animals. b, Laparotomy and oophorectomy treated
animals.
between the oophorectomised animals' hepatic sulphatase
specific activity (n = 12, mean = 2.117 nmoles min' mg-',
range 1.291 to 4.326 nmoles min' mg-') and that observed
in the control (laparotomy) group (n = 12, mean = 2.159
nmoles min ' mg- ', range 0.617 to 4.079 nmoles min 'mg ')
unlike the significant difference observed for the tumour
samples in these animals.
For the tumours that progressed, there was also no signi-
ficant difference between the hepatic sulphatase specific
activity in the animals treated with oestradiol (n = 11,
mean = 2.171 nmoles minm mg-', range 1.468 to 3.324
nmoles min-mg-') and those in the control group treated
with NaCl (n = 12, mean = 2.108 nmolesmin-'mg-', range
1.397 to 2.381 nmoles min ' mg').
Discussion
The Km value is similar in the rat mammary tumour partic-
ulate fraction and in the rat hepatic particulate fraction and
of the same order of magnitude as in other rat tissues
(Conolly & Reski, 1989), and is also similar to the Km value
observed in human breast carcinoma tissue (Prost et al.,
1984). However, the Vmax value is of an order of magnitude
greater in the rat hepatic particulate fraction enzyme than in
the rat mammary tumour particulate fraction, which in turn
is of an order ofmagnitude higher than the value observed in
the particulate fraction of mammary tumour and other tis-
sues in the human (Prost et al., 1984; Urabe et al., 1989).
There is little variation in enzyme activity across a single
tumour, similar values being recorded in different samples
from the same tumour for each of three tumours.
Tumours which regress as a result of oestrogen-deprivation
have a significantly lower intra-tumoural sulphatase level
than those which remain stable. Conversely, this difference is
not observed in the liver of these animals, which acts as an
abundant peripheral tissue source of sulphatase-produced
oestrogens. Previously, it has been reported that the mean
enzyme activity was higher in hormone-responsive tissues,
such as the uterus, in oopherectomised rats than in intact rats
(Loza et al., 1990) although there was no difference observed
in the rat brain or pituitary (Conolly & Resko, 1989).
Consequently, the observation that the hormone-responsive
tumours which regress on endocrine manipulation have a
decreased rather than increased enzyme level is further evi-
dence of the significance of these results. Oestrone sulphate
has been shown to stimulate growth of NMU-induced
tumours in vivo (Santner et al., 1990) but the authors were
unable to establish if the source of sulphatase produced
oestrogens was intra-tumoural or peripheral. The findings of
our study suggest that it is reduction of the intra-tumoural
production of oestrone from oestrone sulphate which is
important in tumour regression induced by oestrogen depri-
vation therapy in hormonal-dependent tumours. This con-
firms the hypothesis that inhibition of oestrone sulphatase
could be a useful therapeutic option in hormonal-dependent
mammary tumours.
Tumours which progress under oestrogenic stimulation do
not have a significantly different intra-tumoural oestrone sul-
phatase level than the control tumours that remain unchang-
ed. In view of our hypothesis, a higher value would have
been expected in the group displaying tumour progression.
There may be several reasons why this was not observed.
Firstly, oestradiol itself is an inhibitor of the oestrone sul-
phatase enzyme (Loza et al., 1990) and despite producing
tumour progression, it may also be inhibiting the enzyme so
that the expected elevated enzyme activity level is no longer
observed. However, in this situation negative feedback inhibi-
tion of the hepatic enzyme would be expected but was not
observed. It is likely that the liver, although an abundant
source of enzyme activity is not under negative feedback
control by oestrogens. Indeed, in the rat, hepatic microsomal
sulphatase is regulated by the sexually dimorphic secretory
pattern of growth hormone (Eriksson et al., 1989). In addi-
tion, oestradiol can produce tumour regression, tumour
progression and also maintenance of baseline tumour size
depending on the dose of added oestradiol. It may well be
that the intra-tumoural oestrone sulphatase also varies in this
situation. Although the tumour progression observed with
oestrogen stimulation was significantly greater than in the
control group, it may be that this degree of progression was
insufficient to be associated with any change in intra-tumou-
ral sulphatase level.
The NMU-induced mammary tumour is a good model of
human breast carcinoma, and this study demonstrates that
reduction of intra-tumoural oestrone sulphatase activity is
associated with tumour regression, although the role of oest-
rone sulphatase in hormone-dependent tumours which subse-
quently progress is still unclear. Nevertheless, these findings
indicate that the development of an oestrone sulphatase
inhibitor could be of therapeutic benefit in the management
of human breast carcinoma.
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